供者淋巴细胞输注联合甲氨蝶呤用于T细胞去除单倍体移植后免疫恢复
一项I/II期研究在CD34+选择单倍体移植后给予预防性供者淋巴细胞输注(DLI)联合甲氨蝶呤预防GVHD,目标DLI剂量5×10^4/kg达到CD4+细胞>100/μL和GVHD目标,2年总生存69%,复发率14%。
要点
- 预防性DLI在+30至+42天给予,最后10例联合利妥昔单抗。
- DLI剂量5×10^4/kg时67%患者CD4+细胞>100/μL,II-IV级急性GVHD 11%。
- 2年估计总生存69%,移植时缓解患者复发率14%。
核心结论
- 延迟预防性DLI联合甲氨蝶呤在目标DLI剂量下与有希望的结果相关。
研究设计与样本
- I/II期研究,35例恶性(n=25)或非恶性疾病(n=10)患者接受CD34+选择单倍体供者外周血干细胞移植。
主要发现
- DLI剂量5×10^4/kg达到CD4/GVHD目标,67%患者CD4+细胞>100/μL,11%发生II-IV级急性GVHD。
- 慢性GVHD累积发生率16%,致死性病毒和真菌感染发生率为11%。
- 2年估计总生存69%,移植时缓解患者复发率14%。
- NK同种反应性对复发无影响。
- 目标DLI剂量5×10^4/kg队列10例中9例存活,中位随访18个月(范围6-29)。
关键数值与推荐
- 研究目标为DLI剂量使≥66%患者在第+120天CD4+细胞>100/μL,且至第+180天II-III级急性GVHD≤33%、III级≤17%、无IV级急性GVHD。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD34+ cell selection minimizes graft-versus-host disease (GVHD) after haploidentical donor stem cell transplant but is associated with slow immune recovery and infections. We report a Phase I/II study of prophylactic donor lymphocyte infusion (DLI) followed by methotrexate (MTX) GVHD prophylaxis after CD34-selected haploidentical donor transplant. A prophylactic DLI was given between day +30 and +42. Rituximab was given with DLI for the last 10 patients. The goal of the study was to determine a DLI dose that would result in a CD4+ cell count > 100/µL at Day +120 in ≥ 66% of patients with ≤ 33% grade II-III, ≤ 17% grade III, and no grade IV acute GVHD by Day +180. Thirty-five patients with malignant (n = 25) or nonmalignant disease (n = 10) were treated after CD34-selected haploidentical donor peripheral blood stem cell transplant. The DLI dose of 5 × 104 /kg met the CD4/GVHD goal with 67% of patients having CD4+ cells > 100/µL and 11% grade II-IV acute GVHD. The cumulative incidence of chronic GVHD was 16%. Fatal viral and fungal infections occurred in 11%. The 2 year estimated overall survival was 69% and the relapse rate was 14% for patients in remission at transplant. There was no effect of NK alloreactivity on relapse. Nine of ten patients at the target DLI dose cohort of 5 × 104 /kg are alive with median follow-up of 18 mos (range 6-29). Delayed prophylactic DLI and MTX was associated with promising outcomes at the target DLI dose. This trial was registered at clinicaltrials.gov, # NCT01027702.
引用
- Gilman AL, Leung W, Cowan MJ, et al. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation. Am J Hematol. 2017. PMID: 29047161. doi:10.1002/ajh.24949
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。